Replies to post #90948 on Ayala Pharmaceuticals Inc (ADXS)

[blueyedcatch]

Splitting up NEO solves the cost concerns for a partner. Taking on all 10 apps for NEO is another,plus milestones, matching taking out the entire platform, like Amgn did. Problem solved.Merck should want the NEO/NSCLC and the HOT/NSCLC,,same story,competition factor going forward. So,Merck should take all the PSA/AXAL,and HOT/PSA,and NEO/PSA if we can do it,and take the NEO/NSCLC and HOT/NSCLC. That would be a huge partnership deal.

[fbg0316]

ADXS released PSA data at ASCO last year bit it wasn't compelling enough for Merck to want to make a deal so PSA could become another AXAL with no interest.